ESC 365 - 2-year real-world outcomes of prasugrel, ticagrelor or clopidogrel therapy following percutaneous coronary intervention from a large multi-centre Australian registry.

ESC Premium Access

2-year real-world outcomes of prasugrel, ticagrelor or clopidogrel therapy following percutaneous coronary intervention from a large multi-centre Australian registry.

Session: Abstract Programme

Topic: Pharmacotherapy

Speaker: Doctor D. Pol (Melbourne, AU)

Event: ESC Asia with APSC & AFC 2020

Congress Presentation

Add to my library

About the speaker

Doctor Derk Pol

Monash Heart, Melbourne (Australia)

0 follower

238 more presentations in this session

3D right ventricular ejection fraction and longitudinal strain are independent predictors of major adverse cardiovascular events in patients with rrhythmogenic right ventricular cardiomyopathy

Speaker: Assistant Professor L. Hosseini (Bojnurd, IR)

A novel pressure-regulated deployment strategy for improving the safety and efficacy of balloon-expandable transcatheter aortic valves

Speaker: Doctor A. Snir (Sydney, AU)

A novel therapeutic approach for coronary inflammation and lymphatic vessels using non-invasive low-intensity pulsed ultrasound in a porcine model with DES-induced coronary hyperconstricting responses

Speaker: Doctor T. Watanabe (Sendai, JP)

A real-world comparison of outcomes between fractional flow reserve-guided versus angiography-guided percutaneous coronary intervention

Speaker: Doctor C. Wong (Sydney, AU)

Adipokine omentin-1 enhances atherosclerotic plaque stability by binding to macrophage integrin receptor

Speaker: Doctor X. Lin (Beijing, CN)

Access the full session

Abstract Programme

Speakers: Doctor D. Pol, Assistant Professor L. Hosseini, Doctor A. Snir, Doctor T. Watanabe, Doctor C. Wong...

About the event

ESC Asia with APSC & AFC 2020

3 December - 5 December 2020

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources